<?xml version="1.0" encoding="UTF-8"?>
<p>In septic patients ascorbate was shown to decrease mortality especially in the hyperinflammatory subphenotype characterized by high leukocyte count (&gt;15,000/ml) and fever (&gt;37.5Â°C) (
 <xref rid="b150-ijmm-46-02-0489" ref-type="bibr">150</xref>). A meta-analysis including 1,210 patients with sepsis showed that different daily doses of intravenous ascorbate were associated with different results, and only a dose between 3-10 g/day resulted in decreased mortality, decreased need for vasopressor and mechanical ventilation, but not lower or higher doses (
 <xref rid="b166-ijmm-46-02-0489" ref-type="bibr">166</xref>).
</p>
